Details for New Drug Application (NDA): 211159
✉ Email this page to a colleague
NDA 211159 describes EZETIMIBE, which is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms Co, Apotex, Aurobindo Pharma, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Ohm Labs Inc, Orient Pharma, Rising, Sandoz, Sciegen Pharms Inc, Teva Pharms Usa, Watson Labs Inc, Zydus Pharms, Ani Pharms, Aurobindo Pharma Usa, and Dr Reddys Labs Sa, and is included in twenty-three NDAs. It is available from twenty-seven suppliers. Additional details are available on the EZETIMIBE profile page.
The generic ingredient in EZETIMIBE is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
The generic ingredient in EZETIMIBE is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
Summary for 211159
| Tradename: | EZETIMIBE |
| Applicant: | Macleods Pharms Ltd |
| Ingredient: | ezetimibe |
| Patents: | 0 |
Pharmacology for NDA: 211159
| Physiological Effect | Decreased Cholesterol Absorption |
Medical Subject Heading (MeSH) Categories for 211159
Suppliers and Packaging for NDA: 211159
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EZETIMIBE | ezetimibe | TABLET;ORAL | 211159 | ANDA | Macleods Pharmaceuticals Limited | 33342-373 | 33342-373-07 | 30 TABLET in 1 BOTTLE (33342-373-07) |
| EZETIMIBE | ezetimibe | TABLET;ORAL | 211159 | ANDA | Macleods Pharmaceuticals Limited | 33342-373 | 33342-373-10 | 90 TABLET in 1 BOTTLE (33342-373-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Apr 29, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
